← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	938	+17	+2%	$22.2B
2	2 Charles River Laboratories CRL $14.4B	336	+34	+11%	$4.96B
3	3 DELISTED CATALENT, INC. CTLT	286	+45	+19%	$5.33B
4	4 DELISTED bluebird bio BLUE	243	+2	+0.8%	$6.9B
5	5 Sarepta Therapeutics SRPT $1.78B	233	+43	+23%	$2.44B
6	6 Precigen PGEN $2.64B	155	-17	-10%	$1.78B
7	7 Ultragenyx Pharmaceutical RARE $1.47B	154	-5	-3%	$2.16B
8	8 DELISTED SANGAMO THERAPEUTICS INC SGMO	148	+5	+3%	$820M
9	9 PTC Therapeutics PTCT $4.98B	129	+15	+13%	$715M
10	SIOX 10 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	114	+1	+0.9%	$718M
11	11 Lineage Cell Therapeutics LCTX $232M	102	-7	-6%	$140M
12	ATHX 12 DELISTED Athersys, Inc. Common Stock ATHX	97	+16	+20%	$51M
13	13 Regenxbio RGNX $454M	89	+3	+3%	$705M
14	BLCM 14 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	88	+4	+5%	$212M
15	15 Intellia Therapeutics NTLA $1.6B	85	0	0%	$439M
16	16 Atara Biotherapeutics ATRA $96M	82	-3	-4%	$441M
17	17 Abeona Therapeutics ABEO $249M	75	+5	+7%	$335M
18	18 Voyager Therapeutics VYGR $124M	75	+23	+44%	$233M
19	19 Fate Therapeutics FATE $232M	74	+14	+23%	$101M
20	20 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	69	-9	-12%	$1.03B
21	ADAP 21 DELISTED Adaptimmune Therapeutics ADAP	67	+11	+20%	$416M
22	AGTC 22 DELISTED Applied Genetic Technologies Corporation AGTC	67	-10	-13%	$33.6M
23	ISEE 23 DELISTED IVERIC bio, Inc. Common Stock ISEE	67	-10	-13%	$63.5M
24	24 CRISPR Therapeutics CRSP $4.86B	64	+25	+64%	$180M
25	25 DELISTED Adverum Biotechnologies ADVM	58	-5	-8%	$49.5M